Gordon, A.C.; Mouncey, P.R.; Al-Beidh, F.; Rowan, K.M.; Nichol, A.D.; Arabi, Y.M.; Annane, D.; Beane, A.; van Bentum-Puijk, W.; Berry, L.R.; Bhimani, Z.; Bonten, M.J.M.; Bradbury, C.A.; Brunkhorst, F.M.; Buzgau, A.; Cheng, A.C.; Detry, M.A.; Duffy, E.J.; Estcourt, L.J.; Fitzgerald, M.; Goossens, H.; Haniffa, R.; Higgins, A.M.; Hills, T.E.; Horvat, C.M.; Lamontagne, F.; Lawler, P.R.; Leavis, H.L.; Linstrum, K.M.; Litton, E.; Lorenzi, E.; Marshall, J.C.; Mayr, F.B.; McAuley, D.F.; McGlothlin, A.; McGuinness, S.P.; McVerry, B.J.; Montgomery, S.K.; Morpeth, S.C.; Murthy, S.; Orr, K.; Parke, R.L.; Parker, J.C.; Patanwala, A.E.; Pettil�, V.; Rademaker, E.; Santos, M.S.; Saunders, C.T.; Seymour, C.W.; Shankar-Hari, M.; Sligl, W.I.; Turgeon, A.F.; Turner, A.M.; van de Veerdonk, F.L.; Zarychanski, R.; Green, C.; Lewis, R.J.; Angus, D.C.; McArthur, C.J.; Berry, S.; Webb, S.A.; Derde, L.P.G.; The REMAP-CAP Investigators
Published 2021
BACKGROUND: The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. METHODS We evaluated tocilizumab and sarilumab in an ongoing international, ...
